Anti Amyloid Kisunla denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for anti amyloid kisunla are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Kisunla as "Not FDA-Approved" — and Why That Denial Is Likely Wrong

Kisunla (donanemab) received full FDA approval for early symptomatic Alzheimer's disease. A "not FDA-approved" denial on an FDA-approved drug almost always reflects a coding error, a lag in Humana's internal drug database, or a plan-document exclusion that predates the approval date. None of these are valid grounds to permanently deny coverage, and each is appealable.

## Why This Denial Happens

Humana's utilization-management system may have been configured before the FDA approval date was formally entered, or the claim may have been submitted under a code the system does not yet associate with the approved indication. In some cases, a plan's formulary exclusion language uses approval status as a proxy, and that language has not been updated to reflect the current regulatory status.

## Federal Appeal Rights

You have layered federal protections:

• ACA §2719 / ERISA §503 internal appeal: Submit a formal written appeal within the timeframe shown on your denial letter (typically 180 days for ERISA plans). The plan must respond within 60 days for standard appeals or 72 hours for expedited appeals involving urgent care.
• Independent external review: If the internal appeal is denied, you are entitled to external review by an accredited Independent Review Organization (IRO). The external-review window is generally within four months of the final internal denial. The IRO's decision is binding on the plan.
• Expedited review: If your treating physician certifies that waiting for a standard timeline would seriously jeopardize your health, request expedited internal and external review simultaneously.

## Documentation to Gather

1. FDA approval confirmation — Print or link the current FDA drug label and approval letter from the FDA website, confirming the approved indication and approval date. 2. Diagnosis confirmation — Obtain records showing your diagnosis of early symptomatic Alzheimer's disease, including cognitive assessments and any amyloid confirmation testing (PET scan or CSF results). 3. Prescriber medical-necessity letter — Ask your neurologist to write a detailed letter stating why Kisunla is medically necessary for your specific case, referencing the confirmed diagnosis and the absence of contraindications per the prescribing label. 4. Plan document language — Request the Summary Plan Description and the specific exclusion language Humana cited; compare it to the drug's current FDA approval status.

## Criteria-Mapping Structure for Your Appeal

Copy each requirement from Humana's denial letter and the FDA-approved prescribing information, then respond with the exact fact from your chart:

| Requirement | Source | Your Chart Evidence | |---|---|---| | FDA-approved indication met | FDA prescribing label | Diagnosis date, ICD-10 code, amyloid confirmation | | Plan exclusion language (if any) | Humana plan document | Approval date vs. exclusion effective date | | Prescriber attestation | Humana coverage policy | Attached physician letter |

Close your appeal letter by citing the FDA approval date explicitly and demanding that Humana identify the specific plan-document language, if any, that supports the denial after that date.